Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.38 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | IL18 | Q14116 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27623409 | 0.72 | TSHR (0.39) | MAOBKDM4ERAB9AALDH1A1GLA | |
| SCHEMBL378478 | 0.69 | CYP19A1 (0.63) | CYP19A1MAOBSLC6A4PARP15PARP10 | |
| SCHEMBL6221184 | 0.69 | RAB9A (0.44) | CYP19A1MAOBHRH3KDM4ERAB9A | |
| SCHEMBL7041250 | 0.69 | PARP15 (0.63) | CYP19A1MAOBSLC6A4PARP15PARP10 | |
| SCHEMBL8852392 | 0.69 | PARP15 (0.63) | CYP19A1MAOBSLC6A4PARP15PARP10 | |
| SCHEMBL7700911 | 0.68 | SLC6A4 (0.62) | CYP19A1MAOBSLC6A4PARP15PARP10 | |
| SCHEMBL6225352 | 0.68 | RAB9A (0.43) | CYP19A1MAOBKDM4ERAB9AMAPT | |
| SCHEMBL6219202 | 0.67 | KMT2A (0.42) | LMNASMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL6221632 | 0.67 | OPRD1 (0.38) | CYP19A1MAOBKDM4ERAB9AMAPT | |
| SCHEMBL6226429 | 0.67 | ABCG2 (0.39) | MAOBSLC6A4KDM4ERAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569644-A4 | INDOLIZINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1598352-A1 | 1-Glyoxylamide indolizines for treating cancer | Synta Pharmaceuticals Corporation (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1569644-A2 | INDOLIZINE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1432709-B1 | 1-GLYOXLYLAMIDE INDOLIZINES FOR TREATING CANCER | SYNTA PHARMACEUTICALS CORP (US) | 2005-07-27 | — | — | EP | disclosed |
| US-6861436-B2 | 1-glyoxylamide indolizines for treating cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040214850-A1 | 1-glyoxylamide indolizines for treating cancer | SYNTA PHARMACEUTICALS CORP. | 2004-10-28 | — | — | US | disclosed |
| WO-2004054507-A2 | INDOLIZINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20030204090-A1 | Indolizine compounds | SYNTA PHARMACEUTICALS CORP. | 2003-10-30 | — | — | US | disclosed |
| US-20030153759-A1 | 1-Glyoxlylamide indolizines for treating cancer | SBR PHARMACEUTICALS CORP. | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214850-A1 | 1-glyoxylamide indolizines for treating cancer | NR2E1, NR4A1, NR0B1 | CYP19A1 156/4885MAOB 1595/4885SLC6A4 1622/4885 |
| US-20030153759-A1 | 1-Glyoxlylamide indolizines for treating cancer | NR4A1, NR0B1, NR2E1 | CYP19A1 246/4885MAOB 1357/4885SLC6A4 1418/4885 |
| US-20030204090-A1 | Indolizine compounds | IDO1, IDO2, PDE4A | CYP19A1 98/4885MAOB 454/4885SLC6A4 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.